Histogenics Corp. (HSGX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS
Histogenics Corp. (NASDAQ:HSGX) announced its quarterly earnings data on Thursday. The company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by $0.21.
Histogenics Corp. (NASDAQ:HSGX) opened at 2.44 on Thursday. The firm’s 50-day moving average is $2.86 and its 200 day moving average is $2.40. Histogenics Corp. has a 1-year low of $1.39 and a 1-year high of $4.59. The company’s market cap is $32.38 million.
In other news, major shareholder Split Rock Partners Ii, Lp acquired 276,801 shares of the firm’s stock in a transaction that occurred on Thursday, September 29th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $622,802.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is owned by corporate insiders.
HSGX has been the topic of several recent analyst reports. William Blair downgraded shares of Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 7th. Zacks Investment Research downgraded shares of Histogenics Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, October 19th. Needham & Company LLC increased their price objective on shares of Histogenics Corp. from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 19th. Finally, BTIG Research raised shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price objective on the stock in a research report on Thursday, August 11th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $7.65.
About Histogenics Corp.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Stock Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related stocks with our FREE daily email newsletter.